相关实验视频

Updated: Jan 11, 2026

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

通过PROTAC介导的CD26的结构功能障碍:对于驱动负性非小细胞肺癌的治疗策略

Guangjian Zhang¹, Bohao Liu¹, Deqian Qiao²

¹Department of Thoracic Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, PR China; Key Laboratory of Enhanced Recovery After Surgery of Integrated Chinese and Western Medicine, Administration of Traditional Chinese Medicine of Shaanxi Province, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, PR China.

|November 14, 2025

概括

有针对性的CD26降解为缺乏驱动突变的非小细胞肺癌 (NSCLC) 患者提供了新的治疗策略. 这种向蛋白质溶解的嵌合体 (PROTAC) 方法降解了CD26,诱导癌细胞死亡,克服了当前疗法的局限性.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药物发现药物发现药物发现

背景情况:

许多非小细胞肺癌 (NSCLC) 患者缺乏可操作的驱动突变,需要新的治疗策略.
现有的向疗法主要集中在EGFR/ALK等突变上,这使得大量患者的服务不足.

研究的目的:

设计和评估CD26向蛋白解向化马体 (PROTACs) 作为驱动负性NSCLC的新治疗方法.
在临床前NSCLC模型中研究CD26降解的作用机制和治疗疗效.

主要方法:

新型针对CD26的PROTACs (P4-1至P4-4) 的合成和表征.
对PROTAC结合亲和力 (SPR) 和三元复合体形成 (NanoBRETTM) 的评估.
评估驱动负性NSCLC细胞系,异种移植和患者衍生器官的降解疗效.

主要成果:

最优的PROTAC,P4-3,通过克拉特林依赖性内细胞分解诱导CD26的降解.
CD26降解导致腺耗尽,ROS积累,DNA损伤和细胞亡在体外和体内.
CD26的降解表现出双重效应,消除了酶和非酶功能.

结论:

有针对性的CD26降解是驱动负性NSCLC的一个有前途的治疗策略.
这种方法克服了当前针对突变的治疗方法的局限性,为选择有限的患者提供了希望.

关键词:

在CD2626中,我们可以看到CD26.分子向疗法分子向疗法非小细胞肺癌是非小细胞肺癌.器官类动物器官类动物针对蛋白质溶解的嵌合体.

更多相关视频

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.